Dive into the forefront of biomarker research with Quanterix's ultra-sensitive instruments! From neurology to oncology, our technology empowers groundbreaking discoveries in diverse fields. ⬇️

#BiomarkerResearch #Neurology #Oncology

ICYMI: 🧠A recent study revealed that the plasma p-Tau217 assay showed comparable accuracies to CSF biomarkers in identifying #Alzheimers disease pathophysiology, emphasizing its potential in advancing AD diagnosis and treatment. Learn more: bit.ly/3Ogw69M

#Biomarkers

Calling all neurology professionals! Don't miss Quanterix at the AAN Annual Meeting in Denver, CO from April 13th to April 18th. Visit booth #1168 to learn about our cutting-edge research and technology advancements shaping the future of neurology.

#AAN2024

Excited to announce our participation in the French Language Neurology Days (JNLF) in Paris! Visit booth #14 to explore our advancements in biomarker detection technology.

#JNLF #Neurology #Biomarkers #Innovation

This #ParkinsonsAwarenessMonth , we want to highlight the latest strides in Parkinson’s disease research. A recent study introduces a homebrew assay for FABP2, shedding light on its potential role in disease progression. Read the study here: bit.ly/43G8cuO

#Neurology

🔍 Interested in the early detection of #Alzheimers using emerging biomarkers like plasma p-Tau181 and p-Tau 217? Join Dr. Andrew Liu and Dr. Blaine R. Roberts as they explore the evolution of AD biomarker research and its future direction. bit.ly/3VA8phg

#Biomarkers

📢 Two days left to register! Join our discussion on the pivotal role of reagent design in achieving increased ultra-sensitive digital biomarker detection. bit.ly/49M5Yfg

#Biomarkers #ClinicalResearch #Webinar

🧠 Neurofilament light (NfL) biomarkers are revolutionizing diagnostics for conditions like MS, AD, and PD. Explore its applications and potential impact on neurological research and treatment ⬇️

#Neurology #Biomarkers

The Simoa® Human Neurology 4-Plex E (N4PE) Simoa® PLUS assay enables the simultaneous measurement of four biomarkers in plasma and CSF. Dive into its applications for neurodegeneration research: bit.ly/43uT9UD

#NeurologyResearch #Biomarkers #SimoaAssay

A recent study in JAMA Neurology is propelling us another step closer to early #Alzheimers detection and treatment.

Using Quanterix’s Simoa® technology, the ALZpath p-Tau217 immunoassay demonstrated remarkable accuracy in identifying AD pathology, on par with CSF biomarkers.

UPCOMING WEBINAR MARCH 28 💻

Join VPs Wesley Straub, Ph.D., and Kishore Malyavantham, Ph.D., as they delve into the role of reagent design and explore how our new Simoa® Advantage PLUS platform optimizes ultra-sensitive #biomarker detection. bit.ly/49M5Yfg

Did you hear the news? 🧠 Quanterix is proud to advance access to high-accuracy Alzheimer's disease testing through our collaborations with multiple health systems. Learn more about this exciting collaboration: bit.ly/48RAiUP

#AlzheimersTesting

#DYK : MS affects 1 in 3000 people worldwide. We are advancing MS research with ultra-sensitive blood-based biomarkers for early detection and disease management. Explore how these biomarkers are shaping the future of MS treatment: bit.ly/3PbgDIk

#MSAwareness #MSWeek

Our #scientists are dedicated to answering your questions daily. Explore our ‘Quanterix Scientist Blog Series,’ where our scientists provide insights into common and current topics resonating with our customer community ⬇️ bit.ly/3wFfzWQ

On #InternationalWomensDay , we celebrate the achievements of women in advancing scientific discovery. Laurie Churchill, our SVP and General Counsel, shared some thoughts on #IWD2024 .

Let's continue striving for inclusivity and the empowerment of women in the STEM industry!

Unlock the potential of blood-based biomarkers in #Alzheimers research. Preview our on-demand webinar to gain insights from Dr. Inge Verberk, Ph.D., on the latest AD research and decision algorithms for interpreting biomarker results. Full recording: bit.ly/49VvuyF

Research suggests that p-Tau 181 is strongly linked to Alzheimer’s markers. Explore the potential of p-tau 181 in advancing neurology research and detection ➡️ bit.ly/3P0oPv9

#Alzheimers #ptau181 #neurology #clinicalresearch

📢 We’re hosting a webinar on March 28 to dive into the latest advancements in our reagent design. Learn how these new features are enhancing precision in biomarker detection.
Registration now open ➡️ bit.ly/49M5Yfg

#BiomarkerDetection #SimoaAdvantagePlus

Quanterix's Simoa® p-Tau 217 blood test has received Breakthrough Device designation from the FDA as an aid in Alzheimer’s Disease evaluation. This breakthrough highlights its potential to revolutionize AD diagnosis. Read more: bit.ly/3P78CV7

#Alzheimers

🧠 Excited to be at #ADPD2024 ! Catch our Product Theater session on March 6 in the Exhibit Hall to hear Dr. Blaine R. Roberts discuss the history of #Alzheimers biomarker research and offer insights into where the field is headed!
Book time with us ➡️ bit.ly/49hsxbM